shutterstock_1862407378_ralf_liebhold
Ralf Liebhold / Shutterstock.com
9 December 2021GenericsAlex Baldwin

Teva loses appeal to invalidate Korlym patent

Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym (mifepristone) was invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.
Americas
15 January 2014   A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.

More on this story

Generics
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.
Americas
15 January 2014   A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.

More on this story

Generics
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.
Americas
15 January 2014   A US judge has said Teva Pharmaceuticals did not infringe patents belonging to a rival company after seeking approval to market a generic version of the drug.